Michael Aristides
55 works · 712 citations · h-index 10
Top works
- Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes
- Cost–utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer
- Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery
- Economic Impact of Increased Clinical Intervention Rates in Community Pharmacy
- Economic Evaluation of Gemcitabine Alone and in Combination with Cisplatin in the Treatment of Nonsmall Cell Lung Cancer
- Clinical outcomes with insulin lispro compared with human regular insulin: a meta-analysis
- Patient Preference and Willingness-to-Pay for Humalog Mix25 Relative to Humulin 30/70: A Multicountry Application of a Discrete Choice Experiment
- Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe
- Cost–effectiveness of vitamin E therapy in the treatment of patients with angiographically proven coronary narrowing (CHAOS trial)
- Cost-Effectiveness of Pergolide Compared to Bromocriptine in the Treatment of Parkinson's Disease: A Decision-Analytic Model
- PCN19 EXAMINING PREFERENCES AND TIMETRADE-OFF UTILITY FOR GEMCITABINE PLUS CISPLATIN IN THE TREATMENT OF BLADDER CANCER:A SURVEY USING DISCRETE CHOICE CONJOINT ANALYSIS IN THE UK
- PCN46 A COST UTILITY ANALYSIS OF MAINTENANCE RITUXIMAB FOR THE TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR NON HODGKINS LYMPHOMA (NHL) IN THE UNITED KINGDOM
- The effects on hospital use and costs of a domiciliary palliative care nursing service.
- PCN4 RETROSPECTIVE COST ANALYSIS OF GEMZARTM IN COMBINATION WITH CISPLATIN IN NON-SMALL CELL LUNG CANCER COMPARED TO OTHER COMBINATION THERAPIES IN GERMANY
- PAR10 COST-EFFECTIVENESS OF RITUXIMAB THERAPY FOR RHEUMATOID ARTHRITIS: A PAN-EUROPEAN ANALYSIS
- 769 Reducing health care burden for the treatment of toxicity associated with pemetrexed or docetaxel in patients with advanced non-small cell lung cancer who previously received chemotherapy: application to the UK setting
- Cost-effectiveness of pemetrexed for previously treated advanced non-small cell lung cancer
- PDB10 THE COST-EFFECTIVENESS OF PIOGLITAZONE IN COMBINATION WITH METFORMIN IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS IN SCOTLAND
- PAR8 USING MABTHERA IN PATIENTS WITH RHEUMATIC ARTHRITIS IN SPAIN: RESULTS OF COST-EFFECTIVENESS DATA BASED ON MICRO-SIMULATION
- Determining patient preferences for improved chemotoxicity during treatment for advanced bladder cancer